The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas
Journal article published in 2020 by
M. R. Chambers,
R. Timothy Bentley,
David K. Crossman,
Jeremy B. Foote 
,
Jey W. Koehler,
James M. Markert,
Nidal B. Omar,
Simon R. Platt,
D. Mitchell Self,
Andy Shores,
Donald C. Sorjonen,
Alicia M. Waters,
Amy B. Yanke,
G. Yancey Gillespie
,
Jey W. Koehler,
James M. Markert,
Nidal B. Omar,
Simon R. Platt,
D. Mitchell Self,
Andy Shores,
Donald C. Sorjonen,
Alicia M. Waters,
Amy B. Yanke,
G. Yancey Gillespie
This paper is made freely available by the publisher.
Full text: Download
Data provided by 